Abpro Holdings, Inc.
ABPO evidence brief
What we can confirm
- BioSniper Score:
- 2.4 / 10
- Market Cap:
- $1.3M
- Lead Asset:
- abp-150 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for ABPO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ABPO
Abpro Holdings, Inc. (ABPO) is a biotechnology company developing tetravalent antibody-based therapeutics for oncology and ophthalmology, with lead candidates ABP-102 and ABP-201 in early clinical development.
Key risk: Going concern risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$1.3M
Cash Runway
—
Lead Asset
abp-150 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Abpro Holdings, Inc..
Similar companies
Abpro Holdings, Inc. (ABPO) is a biotechnology company developing tetravalent antibody-based therapeutics for oncology and ophthalmology, with lead candidates ABP-102 and ABP-201 in early clinical development.
- Lead candidates ABP-102 (HER2/CD3 T-cell engager for HER2-positive solid tumors) and ABP-201 (anti-angiogenic for Wet AMD) use the TetraBi tetravalent antibody format [sec_mda · as of 2026-08-14].
- ABP-102 Phase 1 trials are led by Celltrion, evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy in HER2-positive solid tumors [sec_mda · as of 2026-08-14].
- Shareholders' equity was -$3.5M as of 2026-06-30 [sec].
- Management has expressed substantial doubt about the company's ability to continue operations without additional funding [sec_mda · as of 2026-08-14].
- The company expects to seek funding through equity/debt financings, collaboration agreements, and research grants [sec_mda · as of 2026-08-14].
What works
- Proprietary TetraBi antibody format enables dual-targeting with two binding sites per target, potentially offering differentiated mechanism of action [sec_mda · as of 2026-08-14].
- ABP-102 Phase 1 trials are being led by Celltrion, a partner with clinical development expertise [sec_mda · as of 2026-08-14].
- Pipeline includes a preclinical candidate (ABP-150) targeting CD3 and Claudin 18.2 for gastric cancer, expanding the platform's reach [pipeline].
What to weigh
- Shareholders' equity is negative (-$3.5M as of 2026-06-30), indicating the company is operating at a deficit [sec].
- Management has concluded there is substantial doubt about the company's ability to continue operations without raising additional capital [sec_mda · as of 2026-08-14].
- The company's future viability depends on securing funding through equity/debt, collaborations, or grants, with no guaranteed source [sec_mda · as of 2026-08-14].
- If funding is not obtained, the company may be forced to delay, reduce, or eliminate R&D programs and commercialization efforts [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Lead candidates use TetraBi tetravalent antibody format
“Our two lead product candidates, ABP-102 and ABP-201, feature our next generation tetravalent antibody format, or TetraBi antibody format, which binds to two different targets with two distinct binding sites per target.”
SEC MD&A · August 14, 2026
ABP-102 Phase 1 trials are led by Celltrion
“The Phase 1 clinical trials for ABP-102 are led by Celltrion and aim to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with HER2-positive solid tumors (such as breast and gastric cancers).”
SEC MD&A · August 14, 2026
Management has substantial doubt about company viability
“management has concluded there is substantial doubt as to the Company's”
SEC MD&A · August 14, 2026
Company expects to seek additional funding
“The Company expects to seek additional funding through equity and debt financings, collaboration agreements and research grants.”
SEC MD&A · August 14, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Management has expressed substantial doubt about the company's ability to continue operations without additional funding [sec_mda · as of 2026-08-14].
- Negative shareholders' equity — Shareholders' equity of -$3.5M as of 2026-06-30 indicates the company is operating at a deficit [sec].
- Funding dependency — Future viability depends on raising capital through equity/debt, collaborations, or grants, with no guaranteed source [sec_mda · as of 2026-08-14].
- Clinical trial execution risk — If funding is not obtained, the company may be forced to delay, reduce, or eliminate R&D programs and clinical trials [sec_mda · as of 2026-08-14].
What to watch
- Ability to secure additional funding through equity/debt financings, collaborations, or grants [sec_mda · as of 2026-08-14].
- Progress of ABP-102 Phase 1 clinical trials led by Celltrion [sec_mda · as of 2026-08-14].
- Initiation of planned Phase 1/2 trial for ABP-102 and Phase 1 trials for ABP-201 [sec_mda · as of 2026-05-20].
- Any updates on the preclinical candidate ABP-150 targeting CD3 and Claudin 18.2 [pipeline].
Sources: Pipeline · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run Abpro Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Abpro Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
N/A
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4
Total value held
$1K
| Holder | Shares | Value |
|---|---|---|
| diametric capital, lp | 358,427 | $1K |
| mizuho securities usa llc | 11,386 | $23 |
| barclays plc | 8,333 | $17 |
| flow traders u.s. llc | 51,588 | $0 |
Governance
Frequently asked questions
What is the AI investment thesis for Abpro Holdings, Inc.?
Abpro Holdings, Inc. (ABPO) is a biotechnology company developing tetravalent antibody-based therapeutics for oncology and ophthalmology, with lead candidates ABP-102 and ABP-201 in early clinical development.
What is Abpro Holdings, Inc.'s lead drug candidate?
Abpro Holdings, Inc.'s most advanced tracked candidate is abp-150 (Preclinical) for Gastric cancer.
Who is the CEO of Abpro Holdings, Inc.?
Mr. Jin Wook Suk is the chief executive officer of Abpro Holdings, Inc. (ABPO).
Where is Abpro Holdings, Inc. headquartered?
Abpro Holdings, Inc. (ABPO) is headquartered in Burlington, MA, United States.
What therapeutic areas does Abpro Holdings, Inc. focus on?
Abpro Holdings, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.